IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.283
NA - Nord America 470
EU - Europa 270
OC - Oceania 11
SA - Sud America 10
AF - Africa 6
Totale 4.050
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.757
US - Stati Uniti d'America 455
HK - Hong Kong 248
CN - Cina 233
GB - Regno Unito 81
DE - Germania 56
CZ - Repubblica Ceca 34
IT - Italia 33
IN - India 17
FI - Finlandia 16
NL - Olanda 14
CA - Canada 12
AU - Australia 11
BR - Brasile 8
BE - Belgio 6
UA - Ucraina 6
ZA - Sudafrica 6
JP - Giappone 5
FR - Francia 4
TR - Turchia 4
TW - Taiwan 4
ID - Indonesia 3
PL - Polonia 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AT - Austria 2
CL - Cile 2
EE - Estonia 2
GE - Georgia 2
IE - Irlanda 2
MX - Messico 2
PK - Pakistan 2
SE - Svezia 2
BD - Bangladesh 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ES - Italia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
YE - Yemen 1
Totale 4.050
Salva come PNG Salva come JPEG
Città #
Hong Kong 246
Singapore 172
Ashburn 114
Boardman 93
Hefei 81
London 71
Shanghai 51
Munich 29
Los Angeles 25
Brno 23
Rome 23
San Francisco 23
Redmond 21
Council Bluffs 15
Amsterdam 14
Pune 13
Olomouc 10
Santa Clara 10
Turku 10
Guangzhou 9
Seattle 9
Washington 8
Toronto 7
Helsinki 6
New York 6
São Paulo 6
Melbourne 5
Brooklyn 4
Dallas 4
Manchester 4
Shenzhen 4
Tokyo 4
Beijing 3
Boston 3
Canberra 3
Chicago 3
Haikou 3
Mol 3
Sydney 3
Taipei 3
The Dalles 3
Wuhan 3
Aversa 2
Dublin 2
Genoa 2
Hangzhou 2
Hanover 2
Hasselt 2
Iowa City 2
Johannesburg 2
Lodz 2
Mexico City 2
New Delhi 2
North Liberty 2
Oklahoma City 2
Paris 2
Porto 2
Stockholm 2
Tallinn 2
Tbilisi 2
Tirana 2
West Jordan 2
Xiamen 2
Zhengzhou 2
Almaty 1
Ankara 1
Berlin 1
Brussels 1
Central District 1
Centurion 1
Changchun 1
Changsha 1
Charlotte 1
Chennai 1
Chongqing 1
Clifton 1
Colombo 1
Columbia 1
Concord 1
Dalian 1
Dhaka 1
Frankfurt am Main 1
Fuyang 1
Fuzhou 1
Guiyang 1
Handan 1
Hicksville 1
Jinan 1
Kunming 1
Linfen 1
Lisbon 1
Luoyang 1
Ma'anshan 1
Manila 1
Minsk 1
Montreal 1
Nanning 1
Naples 1
Nuremberg 1
Phoenix 1
Totale 1.230
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 189
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 175
Cancer drugs and QT prolongation: weighing risk against benefit 175
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 174
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 168
Minimal sampling colistin pharmacokinetics in critically ill patients 165
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 164
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 162
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 160
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 152
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 148
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 144
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 130
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 102
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 98
Anthracyclines 97
Anthracycline Cardiotoxicity 93
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 87
Anthracycline Cardiotoxicity 80
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 76
Cardiotoxicity of antitumor drugs 65
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 63
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 61
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 54
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 37
What is cardiotoxicity? 37
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 33
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 31
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 30
Pharmacology of Cardio-Oncology 30
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 29
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 29
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 28
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 28
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 27
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 27
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 25
Isavuconazole: case report and pharmacokinetic considerations 24
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 24
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 24
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 22
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 22
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 22
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 22
Matters of the heart: The case of TNF-alpha targeting drugs 21
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 20
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 20
The concomitant management of cancer therapy and cardiac therapy 20
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 20
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 20
Pharmacological Foundation of Cardio-Oncology 19
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 18
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 18
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 18
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 18
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 18
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 18
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 17
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 17
Doxorubicin degradation in cardiomyocytes 16
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 16
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 16
Translating molecular mechanisms into clinical facts 16
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 16
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 16
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 16
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 15
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 15
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 15
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 15
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 15
Molecular determinants of the reduced cardiotoxicity of epirubicin 15
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 15
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 14
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 14
Do you know pixantrone? 13
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 13
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 12
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 12
The reality of pixantrone in real life 11
Humans and Rodents: The Case of hOAT4 and mOat5 8
Totale 4.129
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.460
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.460
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 4 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/20253.593 74 34 107 13 42 68 37 20 222 238 1.303 1.435
2025/202624 24 0 0 0 0 0 0 0 0 0 0 0
Totale 4.129